Bausch+Lomb releases Vyzulta
Bausch+Lomb has begun rolling out Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) to U.S. pharmaceutical distributors. The Valeant Pharmaceuticals International subsidiary said Vyzulta is slated to become available to patients at pharmacies across the United States in the next few days.